Literature DB >> 24790671

Secondary Acute Lymphoblastic Leukemia after Hodgkin's Lymphoma or a Coincidental Association of Two Hematological Malignancies?

Mihaela Tevet1, Cornel Dragan1, Carmen Saguna1, Doina Barbu1, Anca Roxana Lupu1.   

Abstract

ABSTRACT: Secondary acute lymphoblastic leukaemia (sALL), defined as acute lymphoblastic leukaemia following another malignancy, irrespective of previous treatment, is a rare disease, and its biological characteristics have not been accurately described. We report the case of a 24-year old patient followed for Hodgkin's lymphoma at our clinic, who develops and is diagnosed, less than a year after obtaining complete remission, as having pro-B acute lymphoblastic leukaemia This case has been a real diagnostic and treatment challenge, as sALL following another haematological malignancy is quite rare.
CONCLUSION: It is necessary to better identify the prognostic factors of haematological malignancies in order to prevent the appearance of sALL.

Entities:  

Keywords:  11q23 mutation; Hodgkin's lymphoma; alkilating agents; immunophenotyping; prognostic factors; secondary acute leukaemia

Year:  2013        PMID: 24790671      PMCID: PMC3968475     

Source DB:  PubMed          Journal:  Maedica (Buchar)        ISSN: 1841-9038


  25 in total

Review 1.  Management of acute lymphoblastic leukemia in older patients.

Authors:  Richard A Larson
Journal:  Semin Hematol       Date:  2006-04       Impact factor: 3.851

2.  Childhood secondary ALL after ALL treatment.

Authors:  J Zuna; H Cavé; C Eckert; T Szczepanski; C Meyer; E Mejstrikova; E Fronkova; K Muzikova; E Clappier; D Mendelova; P Boutard; A Schrauder; J Sterba; R Marschalek; J J M van Dongen; O Hrusak; J Stary; J Trka
Journal:  Leukemia       Date:  2007-04-26       Impact factor: 11.528

3.  Second malignancies after treatment for Hodgkin's disease.

Authors:  E Várady; B Deák; Z S Molnár; A Rosta; T Schneider; O Esik; S Eckhardt
Journal:  Leuk Lymphoma       Date:  2001 Nov-Dec

4.  Balanced t(11;15)(q23;q15) in a TP53+/+ breast cancer patient from a Li-Fraumeni syndrome family.

Authors:  Zaki A Sherif; Mark Danielsen
Journal:  Cancer Genet Cytogenet       Date:  2006-07-01

Review 5.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

6.  Lineage switch in acute leukemia.

Authors:  S Stass; J Mirro; S Melvin; C H Pui; S B Murphy; D Williams
Journal:  Blood       Date:  1984-09       Impact factor: 22.113

7.  Correlation of allelic losses and clinicopathological factors in 504 primary breast cancers.

Authors:  Takemitsu Nagahata; Akira Hirano; Yoshihito Utada; Shinichi Tsuchiya; Kaoru Takahashi; Takashi Tada; Masujirou Makita; Fujio Kasumi; Futoshi Akiyama; Goi Sakamoto; Yusuke Nakamura; Mitsuru Emi
Journal:  Breast Cancer       Date:  2002       Impact factor: 4.239

Review 8.  Second cancers in survivors of childhood cancer.

Authors:  Smita Bhatia; Charles Sklar
Journal:  Nat Rev Cancer       Date:  2002-02       Impact factor: 60.716

9.  Germ-line ATM gene alterations are associated with susceptibility to sporadic T-cell acute lymphoblastic leukemia in children.

Authors:  Ella Liberzon; Smadar Avigad; Batia Stark; Julia Zilberstein; Laurence Freedman; Malka Gorfine; Herzel Gavriel; Ian J Cohen; Yacov Goshen; Isaac Yaniv; Rina Zaizov
Journal:  Genes Chromosomes Cancer       Date:  2004-02       Impact factor: 5.006

10.  Ovarian cancer: loss of heterozygosity frequently occurs in the ATM gene, but structural alterations do not occur in this gene.

Authors:  M Koike; S Takeuchi; S Park; Y Hatta; J Yokota; N Tsuruoka; H P Koeffler
Journal:  Oncology       Date:  1999       Impact factor: 2.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.